Snehal Patel Acquires 3,200 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel bought 3,200 shares of the firm’s stock in a transaction dated Monday, December 30th. The shares were bought at an average price of $11.12 per share, with a total value of $35,584.00. Following the completion of the transaction, the chief executive officer now directly owns 5,539,302 shares in the company, valued at approximately $61,597,038.24. This trade represents a 0.06 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Greenwich LifeSciences Price Performance

Greenwich LifeSciences stock opened at $11.74 on Friday. Greenwich LifeSciences, Inc. has a fifty-two week low of $8.00 and a fifty-two week high of $21.44. The firm has a market capitalization of $154.32 million, a price-to-earnings ratio of -14.67 and a beta of 1.61. The company’s 50 day simple moving average is $13.25 and its 200 day simple moving average is $14.24.

Institutional Trading of Greenwich LifeSciences

Hedge funds have recently added to or reduced their stakes in the business. State Street Corp lifted its holdings in shares of Greenwich LifeSciences by 4.4% during the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after purchasing an additional 3,005 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Greenwich LifeSciences by 4.6% during the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after acquiring an additional 5,861 shares during the period. Barclays PLC lifted its position in Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after acquiring an additional 6,538 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Greenwich LifeSciences in the 2nd quarter valued at about $117,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Greenwich LifeSciences during the second quarter worth about $264,000. Institutional investors and hedge funds own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.